{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T07:24:34Z","timestamp":1787037874724,"version":"build-2736575974"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e0 degli Studi di Roma La Sapienza"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Fetuin-A represents a novel molecular target involved in the complex pathogenesis of metabolic disorders. This study aimed to evaluate its association with obesity, type 2 (T2DM) and type 1 (T1DM) diabetes and its correlation with non-invasive liver assessment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>105 patients (38 with obesity without T2DM, 30 with T2DM, and 37 with T1DM) and 13 controls were included. All participants underwent transient elastography (TE) with controlled attenuation parameter (CAP), and liver stiffness measurement (LSM), clinical and biochemical data (including fetuin-A).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fetuin-A was significantly higher in all clinical groups than controls, with the greatest increase observed in obesity without T2DM. Fetuin-A correlated positively with measures of adiposity (BMI, waist circumference, waist to height ratio), triglycerides, and non-invasive indicators of liver steatosis (Fatty Liver Index and CAP), while showing no association with fibrosis (defined by LSM\u2009\u2265\u20097.9\u00a0kPa). In age- and sex-adjusted models, fetuin-A remained independently associated with obesity and T1DM, whereas T2DM showed a negative but not significant association. Fetuin-A was significantly higher in steatosis, with good discriminatory ability (AUC 0.84, 95% CI 0.77\u20130.91) and a sensitivity of 0.75 and specificity of 0.74 at the optimal Youden threshold. Negative association with male sex and positive association with age was also observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Results confirm fetuin-A as a molecular signature of metabolic disorders, mediating the cross-talk between liver and adipose tissue. Further studies are needed to validate it as a useful biomarker for the early diagnosis and monitoring of liver and metabolic disease, including obesity, T2DM, T1DM, and MASLD, and to reach a consensus on reference values definition.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s40618-026-02880-w","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T16:57:52Z","timestamp":1777913872000},"page":"2033-2043","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Fetuin-A: a potential molecular link between obesity, diabetes (type 2 and type 1) and metabolic steatotic liver disease (MASLD)"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-0120-4731","authenticated-orcid":false,"given":"Ilaria","family":"Milani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3694-8229","authenticated-orcid":false,"given":"Gabriele","family":"Ciasca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Chinucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Carnazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5606-8448","authenticated-orcid":false,"given":"Frida","family":"Leonetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8328-2570","authenticated-orcid":false,"given":"Umberto","family":"Basile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1674-6686","authenticated-orcid":false,"given":"Danila","family":"Capoccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"key":"2880_CR1","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.3390\/biomedicines13081854","volume":"13","author":"S Pezzino","year":"2025","unstructured":"Pezzino S, Puleo S, Luca T, Castorina M, Castorina S (2025) Adipokine and Hepatokines in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Current and Developing Trends. Biomedicines 13:1854. https:\/\/doi.org\/10.3390\/biomedicines13081854","journal-title":"Biomedicines"},{"key":"2880_CR2","doi-asserted-by":"publisher","unstructured":"Chekol Abebe E, Tilahun Muche Z, Behaile T, Mariam A, Mengie Ayele T, Mekonnen Agidew M, Teshome Azezew M, Zewde A, Dejenie EA, Mengstie TA (2022) The structure, biosynthesis, and biological roles of fetuin-A: A review. Front Cell Dev Biol 10. https:\/\/doi.org\/10.3389\/fcell.2022.945287","DOI":"10.3389\/fcell.2022.945287"},{"key":"2880_CR3","doi-asserted-by":"publisher","first-page":"6148","DOI":"10.3390\/jcm14176148","volume":"14","author":"K Iwaszko-Sochal","year":"2025","unstructured":"Iwaszko-Sochal K, Kasztelan-Szczerbi\u0144ska B, Cicho\u017c-Lach H (2025) Is There a Diagnostic Miracle on the Horizon? Emerging Biomarkers in MASLD. J Clin Med 14:6148. https:\/\/doi.org\/10.3390\/jcm14176148","journal-title":"J Clin Med"},{"key":"2880_CR4","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","volume":"81","author":"F Tacke","year":"2024","unstructured":"Tacke F, Horn P, Wong VW-S, Ratziu V, Bugianesi E, Francque S, Zelber-Sagi S, Valenti L, Roden M, Schick F, Yki-J\u00e4rvinen H, Gastaldelli A, Vettor R, Fr\u00fchbeck G, Dicker D (2024) EASL\u2013EASD\u2013EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol 81:492\u2013542. https:\/\/doi.org\/10.1016\/j.jhep.2024.04.031","journal-title":"J Hepatol"},{"key":"2880_CR5","doi-asserted-by":"publisher","first-page":"10795","DOI":"10.3390\/ijms251910795","volume":"25","author":"I Milani","year":"2024","unstructured":"Milani I, Codini M, Guarisco G, Chinucci M, Gaita C, Leonetti F, Capoccia D (2024) Hepatokines and MASLD: The GLP1-Ras-FGF21-Fetuin-A Crosstalk as a Therapeutic Target. Int J Mol Sci 25:10795. https:\/\/doi.org\/10.3390\/ijms251910795","journal-title":"Int J Mol Sci"},{"key":"2880_CR6","doi-asserted-by":"publisher","first-page":"3856","DOI":"10.2337\/db13-1794","volume":"63","author":"T Jelenik","year":"2014","unstructured":"Jelenik T, S\u00e9quaris G, Kaul K, Ouwens DM, Phielix E, Kotzka J, Knebel B, Wei\u00df J, Reinbeck AL, Janke L, Nowotny P, Partke H-J, Zhang D, Shulman GI, Szendroedi J, Roden M (2014) Tissue-Specific Differences in the Development of Insulin Resistance in a Mouse Model for Type 1 Diabetes. Diabetes 63:3856\u20133867. https:\/\/doi.org\/10.2337\/db13-1794","journal-title":"Diabetes"},{"key":"2880_CR7","doi-asserted-by":"publisher","first-page":"293","DOI":"10.4274\/jcrpe.4532","volume":"9","author":"\u00dcG \u015eiraz","year":"2017","unstructured":"\u015eiraz \u00dcG, Do\u011fan M, Hatipo\u011flu N, Muhtaro\u011flu S, Kurto\u011flu S (2017) Can Fetuin-A Be a Marker for Insulin Resistance and Poor Glycemic Control in Children with Type 1 Diabetes Mellitus? J Clin Res Pediatr Endocrinol 9:293\u2013299. https:\/\/doi.org\/10.4274\/jcrpe.4532","journal-title":"J Clin Res Pediatr Endocrinol"},{"key":"2880_CR8","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/j.cgh.2024.09.038","volume":"23","author":"M Souza","year":"2025","unstructured":"Souza M, Al-Sharif L, Khalil SM, Villela-Nogueira CA, Mantovani A (2025) Global Epidemiology and Characteristics of Metabolic Dysfunction-associated Steatotic Liver Disease in Type 1 Diabetes Mellitus: An Updated Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 23:1308\u20131319e17. https:\/\/doi.org\/10.1016\/j.cgh.2024.09.038","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2880_CR9","doi-asserted-by":"publisher","first-page":"e84258","DOI":"10.7759\/cureus.84258","volume":"17","author":"S Ahmed","year":"2025","unstructured":"Ahmed S, Ahmed M, Abbas F, Wahab A, Pathan S, Singla B, Ismail S, Khaliq M, Shah MH (2025) Evaluating Hepatokines in the Progression of Non-alcoholic Fatty Acid Liver Disease by Decoding Liver-Derived Molecular Pathologies. Cureus 17:e84258. https:\/\/doi.org\/10.7759\/cureus.84258","journal-title":"Cureus"},{"key":"2880_CR10","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.biochi.2015.12.016","volume":"124","author":"KN Robinson","year":"2016","unstructured":"Robinson KN, Teran-Garcia M (2016) From infancy to aging: Biological and behavioral modifiers of Fetuin-A. Biochimie 124:141\u2013149. https:\/\/doi.org\/10.1016\/j.biochi.2015.12.016","journal-title":"Biochimie"},{"key":"2880_CR11","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40618-017-0697-8","volume":"41","author":"F Roshanzamir","year":"2018","unstructured":"Roshanzamir F, Miraghajani M, Rouhani MH, Mansourian M, Ghiasvand R, Safavi SM (2018) The association between circulating fetuin-A levels and type 2 diabetes mellitus risk: systematic review and meta-analysis of observational studies. J Endocrinol Invest 41:33\u201347. https:\/\/doi.org\/10.1007\/s40618-017-0697-8","journal-title":"J Endocrinol Invest"},{"key":"2880_CR12","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1203\/PDR.0b013e3181bc3f60","volume":"66","author":"M H\u00e4usler","year":"2009","unstructured":"H\u00e4usler M, Sch\u00e4fer C, Osterwinter C, Jahnen-Dechent W (2009) The Physiologic Development of Fetuin-A Serum Concentrations in Children. Pediatr Res 66:660\u2013664. https:\/\/doi.org\/10.1203\/PDR.0b013e3181bc3f60","journal-title":"Pediatr Res"},{"key":"2880_CR13","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.cca.2010.04.020","volume":"411","author":"ER Smith","year":"2010","unstructured":"Smith ER, Ford ML, Tomlinson LA, Rocks BF, Rajkumar C, Holt SG (2010) Poor agreement between commercial ELISAs for plasma fetuin-A: An effect of protein glycosylation? Clin Chim Acta 411:1367\u20131370. https:\/\/doi.org\/10.1016\/j.cca.2010.04.020","journal-title":"Clin Chim Acta"},{"key":"2880_CR14","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"PE Stevens","year":"2024","unstructured":"Stevens PE, Ahmed SB, Carrero JJ, Foster B, Francis A, Hall RK, Herrington WG, Hill G, Inker LA, Kazanc\u0131o\u011flu R, Lamb E, Lin P, Madero M, McIntyre N, Morrow K, Roberts G, Sabanayagam D, Schaeffner E, Shlipak M, Shroff R, Tangri N, Thanachayanont T, Ulasi I, Wong G, Yang C-W, Zhang L, Levin A (2024) KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int 105:S117\u2013S314. https:\/\/doi.org\/10.1016\/j.kint.2023.10.018","journal-title":"Kidney Int"},{"key":"2880_CR15","doi-asserted-by":"publisher","unstructured":"Margraf NG, Jensen-Kondering U, Weiler C, Leypoldt F, Maetzler W, Philippen S, Bartsch T, Fl\u00fch C, R\u00f6cken C, M\u00f6ller B, Royl G, Neumann A, Br\u00fcggemann N, Roeben B, Schulte C, Bender B, Berg D, Kuhlenb\u00e4umer G (2022) Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy: New Data and Quantitative Meta-Analysis. Front Aging Neurosci 14. https:\/\/doi.org\/10.3389\/fnagi.2022.783996","DOI":"10.3389\/fnagi.2022.783996"},{"key":"2880_CR16","doi-asserted-by":"publisher","first-page":"106373","DOI":"10.1016\/j.nbd.2023.106373","volume":"190","author":"J Timsina","year":"2024","unstructured":"Timsina J, Ali M, Do A, Wang L, Western D, Sung YJ, Cruchaga C (2024) Harmonization of CSF and imaging biomarkers in Alzheimer\u2019s disease: Need and practical applications for genetics studies and preclinical classification. Neurobiol Dis 190:106373. https:\/\/doi.org\/10.1016\/j.nbd.2023.106373","journal-title":"Neurobiol Dis"},{"key":"2880_CR17","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-230X-6-33","volume":"6","author":"G Bedogni","year":"2006","unstructured":"Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, Tiribelli C (2006) The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 6:33. https:\/\/doi.org\/10.1186\/1471-230X-6-33","journal-title":"BMC Gastroenterol"},{"key":"2880_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2337\/dc25-S002","volume":"48","author":"American Diabetes Association Professional Practice Committee: 2","year":"2024","unstructured":"American Diabetes Association Professional Practice Committee: 2 (2024) Diagnosis and Classification of Diabetes: Standards of Care in Diabetes\u20142025. Diabetes Care 48:27\u2013S49. https:\/\/doi.org\/10.2337\/dc25-S002","journal-title":"Diabetes Care"},{"key":"2880_CR19","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.3390\/jcm8122033","volume":"8","author":"L Bourebaba","year":"2019","unstructured":"Bourebaba L, Marycz K (2019) Pathophysiological Implication of Fetuin-A Glycoprotein in the Development of Metabolic Disorders: A Concise Review. J Clin Med 8:2033. https:\/\/doi.org\/10.3390\/jcm8122033","journal-title":"J Clin Med"},{"key":"2880_CR20","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s12020-016-1132-1","volume":"55","author":"D P\u00e9rez-Sotelo","year":"2017","unstructured":"P\u00e9rez-Sotelo D, Roca-Rivada A, Larrosa-Garc\u00eda M, Castelao C, Baamonde I, Baltar J, Crujeiras AB, Seoane LM, Casanueva FF, Pardo M (2017) Visceral and subcutaneous adipose tissue express and secrete functional alpha2hsglycoprotein (fetuin a) especially in obesity. Endocrine 55:435\u2013446. https:\/\/doi.org\/10.1007\/s12020-016-1132-1","journal-title":"Endocrine"},{"key":"2880_CR21","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1186\/s12944-018-0919-x","volume":"17","author":"A Khadir","year":"2018","unstructured":"Khadir A, Kavalakatt S, Madhu D, Hammad M, Devarajan S, Tuomilehto J, Tiss A (2018) Fetuin-A levels are increased in the adipose tissue of diabetic obese humans but not in circulation. Lipids Health Dis 17:291. https:\/\/doi.org\/10.1186\/s12944-018-0919-x","journal-title":"Lipids Health Dis"},{"key":"2880_CR22","doi-asserted-by":"publisher","first-page":"625","DOI":"10.3390\/metabo12070625","volume":"12","author":"Q Etienne","year":"2022","unstructured":"Etienne Q, Lebrun V, Komuta M, Navez B, Thissen J-P, Leclercq IA, Lanthier N (2022) Fetuin-A in Activated Liver Macrophages Is a Key Feature of Non-Alcoholic Steatohepatitis. Metabolites 12:625. https:\/\/doi.org\/10.3390\/metabo12070625","journal-title":"Metabolites"},{"key":"2880_CR23","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/s12876-024-03310-y","volume":"24","author":"MM Elhoseeny","year":"2024","unstructured":"Elhoseeny MM, Abdulaziz BA, Mohamed MA, Elsharaby RM, Rashad GM, Othman AAA (2024) Fetuin-A: a relevant novel serum biomarker for non-invasive diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD): a retrospective case-control study. BMC Gastroenterol 24:226. https:\/\/doi.org\/10.1186\/s12876-024-03310-y","journal-title":"BMC Gastroenterol"},{"key":"2880_CR24","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1530\/EJE-11-0864","volume":"166","author":"JW Haukeland","year":"2012","unstructured":"Haukeland JW, Dahl TB, Yndestad A, Gladhaug IP, L\u00f8berg EM, Haaland T, Konopski Z, Wium C, Aasheim ET, Johansen OE, Aukrust P, Halvorsen B, Birkeland KI (2012) Fetuin A in nonalcoholic fatty liver disease: in vivo and in vitro studies. Eur J Endocrinol 166:503\u2013510. https:\/\/doi.org\/10.1530\/EJE-11-0864","journal-title":"Eur J Endocrinol"},{"key":"2880_CR25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.14218\/JCTH.2020.00081","volume":"9","author":"S Liu","year":"2021","unstructured":"Liu S, Xiao J, Zhao Z, Wang M, Wang Y, Xin Y (2021) Systematic Review and Meta-analysis of Circulating Fetuin-A Levels in Nonalcoholic Fatty Liver Disease. J Clin Transl Hepatol 9:3\u201314. https:\/\/doi.org\/10.14218\/JCTH.2020.00081","journal-title":"J Clin Transl Hepatol"},{"key":"2880_CR26","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1007\/s12020-012-9754-4","volume":"42","author":"S Rasul","year":"2012","unstructured":"Rasul S, Wagner L, Kautzky-Willer A (2012) Fetuin-A and angiopoietins in obesity and type 2 diabetes mellitus. Endocrine 42:496\u2013505. https:\/\/doi.org\/10.1007\/s12020-012-9754-4","journal-title":"Endocrine"},{"key":"2880_CR27","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1001\/jama.300.2.182","volume":"300","author":"JH Ix","year":"2008","unstructured":"Ix JH, Wassel CL, Kanaya AM, Vittinghoff E, Johnson KC, Koster A, Cauley JA, Harris TB, Cummings SR, Shlipak MG (2008) Health ABC Study, for the: Fetuin-A and Incident Diabetes Mellitus in Older Persons. JAMA 300:182\u2013188. https:\/\/doi.org\/10.1001\/jama.300.2.182","journal-title":"JAMA"},{"key":"2880_CR28","doi-asserted-by":"publisher","first-page":"2762","DOI":"10.2337\/db08-0538","volume":"57","author":"N Stefan","year":"2008","unstructured":"Stefan N, Fritsche A, Weikert C, Boeing H, Joost H-G, H\u00e4ring H-U, Schulze MB (2008) Plasma Fetuin-A Levels and the Risk of Type 2 Diabetes. Diabetes 57:2762\u20132767. https:\/\/doi.org\/10.2337\/db08-0538","journal-title":"Diabetes"},{"key":"2880_CR29","doi-asserted-by":"publisher","first-page":"468","DOI":"10.2337\/diacare.29.02.06.dc05-1484","volume":"29","author":"K Mori","year":"2006","unstructured":"Mori K, Emoto M, Yokoyama H, Araki T, Teramura M, Koyama H, Shoji T, Inaba M, Nishizawa Y (2006) Association of Serum Fetuin-A With Insulin Resistance in Type 2 Diabetic and Nondiabetic Subjects. Diabetes Care 29:468. https:\/\/doi.org\/10.2337\/diacare.29.02.06.dc05-1484","journal-title":"Diabetes Care"},{"key":"2880_CR30","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.dsx.2014.09.009","volume":"9","author":"A Esteghamati","year":"2015","unstructured":"Esteghamati A, Afarideh M, Feyzi S, Noshad S, Nakhjavani M (2015) Comparative effects of metformin and pioglitazone on fetuin-A and osteoprotegerin concentrations in patients with newly diagnosed diabetes: A randomized clinical trial. Diabetes Metabolic Syndrome: Clin Res Reviews 9:258\u2013265. https:\/\/doi.org\/10.1016\/j.dsx.2014.09.009","journal-title":"Diabetes Metabolic Syndrome: Clin Res Reviews"},{"key":"2880_CR31","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.clinre.2020.01.007","volume":"44","author":"L-Y Zhang","year":"2020","unstructured":"Zhang L-Y, Qu X-N, Sun Z-Y, Zhang Y (2020) Effect of liraglutide therapy on serum fetuin A in patients with type 2 diabetes and non-alcoholic fatty liver disease. Clin Res Hepatol Gastroenterol 44:674\u2013680. https:\/\/doi.org\/10.1016\/j.clinre.2020.01.007","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"2880_CR32","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3803\/EnM.2015.30.2.177","volume":"30","author":"J Lee","year":"2015","unstructured":"Lee J, Hong S-W, Park SE, Rhee E-J, Park C-Y, Oh K-W, Park S-W, Lee W-Y (2015) Exendin-4 Inhibits the Expression of SEPP1 and Fetuin-A via Improvement of Palmitic Acid-Induced Endoplasmic Reticulum Stress by AMPK. Endocrinol Metab 30:177\u2013184. https:\/\/doi.org\/10.3803\/EnM.2015.30.2.177","journal-title":"Endocrinol Metab"},{"key":"2880_CR33","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.metabol.2008.04.019","volume":"57","author":"K Mori","year":"2008","unstructured":"Mori K, Emoto M, Araki T, Yokoyama H, Lee E, Teramura M, Koyama H, Shoji T, Inaba M, Nishizawa Y (2008) Effects of pioglitazone on serum fetuin-A levels in patients with type 2 diabetes mellitus. Metabolism - Clin Experimental 57:1248\u20131252. https:\/\/doi.org\/10.1016\/j.metabol.2008.04.019","journal-title":"Metabolism - Clin Experimental"},{"key":"2880_CR34","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1111\/liv.12478","volume":"35","author":"M Sato","year":"2015","unstructured":"Sato M, Kamada Y, Takeda Y, Kida S, Ohara Y, Fujii H, Akita M, Mizutani K, Yoshida Y, Yamada M, Hougaku H, Takehara T, Miyoshi E (2015) Fetuin-A negatively correlates with liver and vascular fibrosis in nonalcoholic fatty liver disease subjects. Liver Int 35:925\u2013935. https:\/\/doi.org\/10.1111\/liv.12478","journal-title":"Liver Int"},{"key":"2880_CR35","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1258\/acb.2010.010169","volume":"47","author":"Y Yilmaz","year":"2010","unstructured":"Yilmaz Y, Yonal O, Kurt R, Ari F, Oral AY, Celikel CA, Korkmaz S, Ulukaya E, Ozdogan O, Imeryuz N, Avsar E, Kalayci C (2010) Serum fetuin A\/\u03b12HS-glycoprotein levels in patients with non-alcoholic fatty liver disease: relation with liver fibrosis. Ann Clin Biochem 47:549\u2013553. https:\/\/doi.org\/10.1258\/acb.2010.010169","journal-title":"Ann Clin Biochem"},{"key":"2880_CR36","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1515\/jpem-2014-0290","volume":"28","author":"SMAE Dayem","year":"2015","unstructured":"Dayem SMAE, Battah AA, Bohy AEME, Shehaby AE (2015) Evaluation of fetuin-A and carotid intima-media thickness in adolescent type 1 diabetic patients. J Pediatr Endocrinol Metab 28:287\u2013292. https:\/\/doi.org\/10.1515\/jpem-2014-0290","journal-title":"J Pediatr Endocrinol Metab"},{"key":"2880_CR37","doi-asserted-by":"publisher","first-page":"101684","DOI":"10.1016\/j.diabet.2025.101684","volume":"51","author":"A Mantovani","year":"2025","unstructured":"Mantovani A, Ciardullo S, Sani E, Csermely A, Shtembari E, Milani I, Sbraccia P, Perseghin G, Leonetti F, Targher G, Guglielmi V, Capoccia D (2025) Association between continuous glucose monitoring metrics and metabolic dysfunction-associated steatotic liver disease in adults with type 1 diabetes undergoing vibration-controlled transient elastography: a multicenter cross-sectional study. Diabetes Metab 51:101684. https:\/\/doi.org\/10.1016\/j.diabet.2025.101684","journal-title":"Diabetes Metab"},{"key":"2880_CR38","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-025-02621-5","author":"JL Herrera-Ojeda","year":"2025","unstructured":"Herrera-Ojeda JL, Blanco-Palma RS, Ch\u00e1vez-Tapia NC, Uribe M, Montalvo-Jav\u00e9 EE, Nu\u00f1o-L\u00e1mbarri N (2025) The pathophysiological link between type 1 diabetes and MASLD: insights into insulin resistance and liver dysfunction. J Endocrinol Invest. https:\/\/doi.org\/10.1007\/s40618-025-02621-5","journal-title":"J Endocrinol Invest"},{"key":"2880_CR39","doi-asserted-by":"publisher","first-page":"204201882110555","DOI":"10.1177\/20420188211055557","volume":"12","author":"J Mertens","year":"2021","unstructured":"Mertens J, Van Gaal LF, Francque SM, De Block C (2021) NAFLD in type 1 diabetes: overrated or underappreciated? Therapeutic Adv Endocrinol 12:20420188211055557. https:\/\/doi.org\/10.1177\/20420188211055557","journal-title":"Therapeutic Adv Endocrinol"},{"key":"2880_CR40","doi-asserted-by":"publisher","unstructured":"Mertens J, De Block C, Spinhoven M, Driessen A, Francque SM, Kwanten WJ (2021) Hepatopathy Associated With Type 1 Diabetes: Distinguishing Non-alcoholic Fatty Liver Disease From Glycogenic Hepatopathy. Front Pharmacol 12. https:\/\/doi.org\/10.3389\/fphar.2021.768576","DOI":"10.3389\/fphar.2021.768576"},{"key":"2880_CR41","doi-asserted-by":"publisher","unstructured":"Shaheen A-A, Baguley E, Swain MG, Tam M, Ma MM, Sebastiani G, Jiang J, Lee F, Medellin A, Abraldes JG (2026) Diabetes and obesity reduce FIB-4 accuracy in MASLD referral pathways. JHEPReport 8. https:\/\/doi.org\/10.1016\/j.jhepr.2026.101735","DOI":"10.1016\/j.jhepr.2026.101735"},{"key":"2880_CR42","doi-asserted-by":"publisher","first-page":"6627","DOI":"10.3390\/ijms22126627","volume":"22","author":"T Dogru","year":"2021","unstructured":"Dogru T, Kirik A, Gurel H, Rizvi AA, Rizzo M, Sonmez A (2021) The Evolving Role of Fetuin-A in Nonalcoholic Fatty Liver Disease: An Overview from Liver to the Heart. Int J Mol Sci 22:6627. https:\/\/doi.org\/10.3390\/ijms22126627","journal-title":"Int J Mol Sci"},{"key":"2880_CR43","doi-asserted-by":"publisher","first-page":"139","DOI":"10.4103\/1319-3767.157556","volume":"21","author":"G Celebi","year":"2015","unstructured":"Celebi G, Genc H, Gurel H, Sertoglu E, Kara M, Tapan S, Acikel C, Karslioglu Y, Ercin CN, Dogru T (2015) The Relationship of Circulating Fetuin-A With Liver Histology and Biomarkers of Systemic Inflammation in Nondiabetic Subjects with Nonalcoholic Fatty Liver Disease. Saudi J Gastroenterol 21:139\u2013145. https:\/\/doi.org\/10.4103\/1319-3767.157556","journal-title":"Saudi J Gastroenterol"},{"key":"2880_CR44","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.clinbiochem.2012.02.024","volume":"45","author":"C Bellia","year":"2012","unstructured":"Bellia C, Tomaiuolo R, Caruso A, Sasso BL, Zarrilli F, Carru C, Deiana M, Zinellu A, Pinna S, Castaldo G, Deiana L, Ciaccio M (2012) Fetuin-A serum levels are not correlated to kidney function in long-lived subjects. Clin Biochem 45:637\u2013640. https:\/\/doi.org\/10.1016\/j.clinbiochem.2012.02.024","journal-title":"Clin Biochem"},{"key":"2880_CR45","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.diabres.2014.07.002","volume":"106","author":"A Obuchi","year":"2014","unstructured":"Obuchi A, Adachi H, Enomoto M, Fukami A, Kumagai E, Nakamura S, Yoshimura A, Nohara Y, Nakao E, Umeki Y, Fukumoto Y, Imaizumi T (2014) High plasma fetuin-A levels are associated with metabolic syndrome among males but not females in a Japanese general population. Diabetes Res Clin Pract 106:128\u2013135. https:\/\/doi.org\/10.1016\/j.diabres.2014.07.002","journal-title":"Diabetes Res Clin Pract"},{"key":"2880_CR46","doi-asserted-by":"publisher","first-page":"529","DOI":"10.31662\/jmaj.2024-0104","volume":"7","author":"S Eswar","year":"2024","unstructured":"Eswar S, Rajagopalan B, Ete K, Gattem SNR (2024) Clinical and Biochemical Parameters in Relation to Serum Fetuin-A Levels in Overweight and Obese with and without Metabolic Syndrome in the North-eastern States of Indian Population. JMA J 7:529\u2013535. https:\/\/doi.org\/10.31662\/jmaj.2024-0104","journal-title":"JMA J"},{"key":"2880_CR47","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.2337\/dc12-1870","volume":"36","author":"GA Laughlin","year":"2013","unstructured":"Laughlin GA, Barrett-Connor E, Cummins KM, Daniels LB, Wassel CL, Ix JH (2013) Sex-Specific Association of Fetuin-A With Type 2 Diabetes in Older Community-Dwelling AdultsThe Rancho Bernardo Study. Diabetes Care 36:1994\u20132000. https:\/\/doi.org\/10.2337\/dc12-1870","journal-title":"Diabetes Care"},{"key":"2880_CR48","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/pmic.201100127","volume":"12","author":"H Liu","year":"2012","unstructured":"Liu H, Choi J-W, Yun JW (2012) Gender differences in rat plasma proteome in response to high-fat diet. Proteomics 12:269\u2013283. https:\/\/doi.org\/10.1002\/pmic.201100127","journal-title":"Proteomics"},{"key":"2880_CR49","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1159\/000363022","volume":"34","author":"SW Kim","year":"2014","unstructured":"Kim SW, Choi J-W, Lee DS, Yun JW (2014) Sex Hormones Regulate Hepatic Fetuin Expression in Male and Female Rats. Cell Physiol Biochem 34:554\u2013564. https:\/\/doi.org\/10.1159\/000363022","journal-title":"Cell Physiol Biochem"},{"key":"2880_CR50","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12902-020-0538-1","volume":"20","author":"S Liu","year":"2020","unstructured":"Liu S, Hu W, He Y, Li L, Liu H, Gao L, Yang G, Liao X (2020) Serum Fetuin-A levels are increased and associated with insulin resistance in women with polycystic ovary syndrome. BMC Endocr Disorders 20:67. https:\/\/doi.org\/10.1186\/s12902-020-0538-1","journal-title":"BMC Endocr Disorders"},{"key":"2880_CR51","doi-asserted-by":"publisher","first-page":"855","DOI":"10.3390\/biomedicines13040855","volume":"13","author":"I Milani","year":"2025","unstructured":"Milani I, Chinucci M, Leonetti F, Capoccia D (2025) MASLD: Prevalence, Mechanisms, and Sex-Based Therapies in Postmenopausal Women. Biomedicines 13:855. https:\/\/doi.org\/10.3390\/biomedicines13040855","journal-title":"Biomedicines"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-026-02880-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-026-02880-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-026-02880-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T06:30:02Z","timestamp":1787034602000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-026-02880-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":51,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["2880"],"URL":"https:\/\/doi.org\/10.1007\/s40618-026-02880-w","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,4]]},"assertion":[{"value":"7 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declared no competing interests.","order":1,"name":"Ethics","label":"<b>Conflict of interest<\/b>","group":{"name":"EthicsHeading","label":"Declarations"}}]}}